Hangzhou 皓阳生物 is a technology platform company specializing in contract development for biologic drugs, particularly antibody therapeutics. Founded in November 2015 and based in Hangzhou, the company provides antibody drug preclinical development services to global biopharma and biotech clients. Its capabilities include early discovery support, CMC process development, clinical-sample production, and commercialization-scale manufacturing. The company positions itself to accelerate new drug R&D and reduce overall development costs for customers. After completing a ¥50 million Series A financing, Haoyang plans to expand its R&D team, strengthen hardware infrastructure, and improve service processes. The funding is intended to broaden and deepen its antibody preclinical R&D service offerings to better serve customers and partners in new drug development. Healsun Biopharm is a Chinese contract development and manufacturing organisation (CDMO) serving biopharma customers. The company has raised nearly 250 million yuan (about $36.7 million) in a Series B round. The article does not provide details on the use of proceeds or specific future plans. No operating metrics, past funding rounds, founding year, or location beyond China were reported. Participating investors were not named in the coverage. The report appeared as part of a China digest summarizing regional deal activity.

Total raised

$44M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2023